Core Viewpoint - The IPO process of Beijing Plant Doctor Cosmetics Co., Ltd. is progressing, but the company faces significant challenges including stagnating growth, compliance risks, business model pressures, and governance issues in a highly competitive domestic beauty market [1][12]. Financial Performance - From 2022 to 2024, the company's revenue was 2.117 billion, 2.151 billion, and 2.156 billion yuan, with a declining growth rate from 1.60% to 0.22%, resulting in a three-year compound growth rate of only 0.91%, indicating near stagnation [2][13]. - Net profit figures for the same period were 158 million, 230 million, and 243 million yuan, with growth rates fluctuating dramatically, dropping from 45.35% in 2023 to 5.79% in 2024, raising uncertainties about achieving positive growth in 2025 [4][15]. - The company's performance has lagged behind the industry, with the Chinese beauty market expected to grow from 590 billion yuan in 2019 to 850 billion yuan in 2024, reflecting a compound annual growth rate of 7.6% [6][17]. Cash Flow and Investment Structure - The net cash flow from operating activities showed significant volatility, with figures of 341 million, 501 million, 381 million, and 194 million yuan, and a notable decline of 23.97% in 2024 [7][17]. - The company has heavily relied on marketing over research and development, with sales expenses reaching 703 million, 739 million, 743 million, and 365 million yuan, consistently accounting for 33%-38% of revenue, totaling nearly 2.185 billion yuan over three years [7][18]. - Research and development expenditures were 73.77 million, 75.88 million, 66.33 million, and 29.69 million yuan, decreasing from 3.48% to 3.08% of revenue, with the number of R&D personnel dropping from 166 to 117 [7][18]. Business Model and Market Position - The company's sales heavily depend on a distribution model, with revenue from distributors accounting for 62%-65% of total sales, leading to lower gross margins compared to direct sales competitors [8][18]. - The gross margins for the company were 55.23%, 60.35%, 58.9%, and 60.99%, while comparable companies with direct sales had gross margins between 66.69% and 72.16% [8][18]. - The inventory turnover rate decreased from 4.96 times per year to 4.27 times per year, indicating a slowdown in product sales and accumulating price risk [8][18]. Compliance and Governance Issues - The company has faced multiple administrative penalties, including fines for false advertising and product safety violations, reflecting weak internal controls [9][20]. - As of October 31, 2025, 26 of the company's direct stores have not obtained the necessary health permits, posing ongoing compliance risks [10][21]. - Consumer complaints have reached 417, indicating a crisis in brand reputation due to issues like false advertising and poor service [10][21]. IPO Motivation and Financial Strategy - The company holds significant financial assets, including 853 million yuan in trading financial assets and 202 million yuan in cash, suggesting it is not in urgent need of funds [22]. - The company distributed a total of 180 million yuan in cash dividends in 2024 and 2025, raising questions about the rationale behind seeking nearly 1 billion yuan through the IPO while simultaneously providing large dividends to the controlling shareholder [11][22]. - The IPO plan includes allocating over half of the raised funds for marketing, which raises concerns about the urgency and justification of the fundraising effort [11][22].